Jonathan C. Y. Tang  PhD. MSc. BSc. FIBMS

Over 20 years experience in the field of clinical chemistry and research into metabolic bone disease. Currently a HCPC registered advanced Biomedical Scientist in Biochemistry and a fellow member of the Institute of Biomedical Science (IBMS). Previously held position as a senior Biomedical Scientist of the liquid chromatography tandem mass spectrometry (LC-MS/MS) section at the Department of Clinical Biochemistry and Metabolic Medicine, Royal Liverpool and Broadgreen University Hospital NHS Trust (2001-2011). Appointed senior research associate, Norwich Medical school, University of East Anglia (UEA) (2011-2016), then promoted to research fellow in metabolic bone disease since 2016.

In 2011, working closely with Prof. William (Bill) Fraser, established Bioanalytical facility (BAF); a multidisciplinary lab facility specialised in fully/semi-automated/manual HPLC-MS/MS, isotopic/non-isotopic immunoassay, and wet chemistry techniques. BAF is accredited by the Central Pathology Accreditation (CPA) and certified for Good Clinical Laboratory Practice (GCLP). I lead a team of research technicians, post-doctoral research associates, biomedical scientists and clinical scientists from UEA and the Norfolk and Norwich University Hospital NHS trust (NNUHFT). I also co-supervise MRes, PhD, BSc. and MBBS students.

I specialise in biochemical analysis of small molecules, proteins and peptides, used in diagnostics and clinical research studies in metabolic bone disease. My research focuses on vitamin D metabolites, bone remodelling/turnover biomarkers, osteoanabolics and homeostatic markers of calcium/phosphate metabolism. Key publications include development of LC-MS/MS assays for vitamin D metabolites (1,25-dihydrox vitamin D, 25-hydroxyvitamin D and 24, 25-dihydroxyvitamin D), and bone turnover markers in the study of their relationships in health and in disease, studies on the effects of vitamin D supplementation/exercise in sport athletes and in general populations. Currently hold grant funding from government, Pharma and research councils for studies in bone stress fracture and treatment using PTH therapeutics.